Clinical Trial Update: Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept. [Phase 4]

View source ↗

Summary

A Phase 4 proof-of-concept study evaluating the effectiveness of combining exenatide with dapagliflozin on 24-hour glucose variability measured by continuous gl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• EXENATIDE (EXENATIDE)

Snippet

Sponsor: Consano Clinical Research, LLC | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED